Dr. Jackman on Overcoming Resistance to EGFR Inhibitors in Lung Cancer
David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non–small cell lung cancer (NSCLC).
David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non—small cell lung cancer (NSCLC).
When patients develop resistance to their first EGFR inhibitors, they often have T790M mutations. This lead to the development of osimertinib (Tagrisso), adds Jackman.
Resistance in NSCLC is very specific, says Jackman, and as resistance becomes better understood, more targeted therapies can be developed.
